Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Median effective dose of alfentanil with etomidate for suppressing cardiovascular responses to laryngeal mask insertion in elderly patients
ChiCTR2500109783Phase 4Not yet recruiting
- Sponsor
- Hangzhou Third People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alfentanil in None, sponsored by Hangzhou Third People's Hospital. Primary endpoint: Cardiovascular reaction to laryngeal mask insertion. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
alfentanil
Beyond the preview
Go deeper on ChiCTR2500109783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109783.